Related Experiment Video
Updated: Aug 9, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Phenyl Dihydrouracil: An Alternative Cereblon Binder for PROTAC Design
Jamie A Jarusiewicz1, Satoshi Yoshimura2, Anand Mayasundari1
1Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
New phenyl dihydrouracil (PD)-based Proteolysis Targeting Chimeras (PROTACs) offer enhanced chemical stability and protein degradation efficacy compared to traditional thalidomide analogues. These PD-PROTACs overcome limitations of previous designs, improving cellular potency.
Area of Science:
- Medicinal Chemistry
- Chemical Biology
- Drug Discovery
Background:
- Thalidomide analogues are crucial in Proteolysis Targeting Chimera (PROTAC) development but suffer from inherent chemical instability, particularly hydrolysis in cell culture media.
- Phenyl glutarimide (PG)-based PROTACs demonstrated improved stability and protein degradation compared to traditional analogues.
- Optimization efforts focused on enhancing stability and removing chiral centers present in PG-based PROTACs.
Purpose of the Study:
- To design and synthesize novel phenyl dihydrouracil (PD)-based PROTACs.
- To evaluate and compare the physicochemical and pharmacological properties of PD-PROTACs against IMiD and PG analogues.
- To assess the potential of PD-PROTACs as a more stable and effective alternative in targeted protein degradation.
Main Methods:
- Design and synthesis of LCK-directing PD-PROTACs.
- Comparative analysis of chemical stability under physiological conditions.
- Evaluation of protein degradation efficacy and cellular potency in vitro.
- Assessment of physicochemical properties including solubility and stability.
Main Results:
- PD-PROTACs exhibited superior chemical stability compared to IMiD and PG analogues.
- The developed PD-PROTACs demonstrated efficient LCK protein degradation.
- Elimination of the chiral center in PD-based PROTACs resolved racemization issues and improved overall performance.
- PD-PROTACs showed enhanced cellular potency and improved pharmacokinetic profiles.
Conclusions:
- Phenyl dihydrouracil (PD)-based PROTACs represent a significant advancement in PROTAC technology, offering enhanced chemical stability and protein degradation efficiency.
- PD-PROTACs provide a promising platform for developing next-generation therapeutics with improved drug-like properties.
- The design strategy overcomes key limitations of existing thalidomide-based PROTACs, paving the way for more robust targeted protein degraders.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
07:22Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024